Mode
Text Size
Log in / Sign up
N/A N=75,771

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer · Squamous Cell Carcinoma · Basal Cell Carcinoma

Enrolled (actual)
75,771
Serious AEs
Results posted
Jan 2025
Primary outcome: Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Exposure of skin cancer of interest (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Momentum Data
Primary completion
Mar 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo
133; 812
PRIMARY
Number of New Onset Skin Cancers in the Female Sex Subgroup
78; 429
PRIMARY
Number of New Onset Skin Cancers in the Male Sex Subgroup
55; 383
PRIMARY
Number of New Onset Skin Cancers in the <45 Age Subgroup
11; 72
PRIMARY
Number of New Onset Skin Cancers in the 45-64 Age Subgroup
42; 315
PRIMARY
Number of New Onset Skin Cancers in the >=65 Age Subgroup
80; 425
PRIMARY
Number of New Onset Skin Cancers in the White Ethnicity Subgroup
103; 563
PRIMARY
Number of New Onset Skin Cancers in the Non-white Ethnicity Subgroup
9; 66
PRIMARY
Number of New Onset Skin Cancers in the Most Deprived Subgroup
46; 345
PRIMARY
Number of New Onset Skin Cancers in the Least Deprived Subgroup
66; 355
SECONDARY
Prevalence of Skin Cancer in Adult People Diagnosed With Vitiligo
66; 293
SECONDARY
Prevalence of Melanoma Skin Cancer in Adult People Diagnosed With Vitiligo
85; 27
SECONDARY
Prevalence of Squamous Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo
13; 72
SECONDARY
Prevalence of Basal Cell Carcinoma Skin Cancer in Adult People Diagnosed With Vitiligo
31; 161
SECONDARY
Number of New Onset Actinic Keratoses in Adult People Diagnosed With Vitiligo
264; 1108
SECONDARY
Prevalence of Actinic Keratoses in Adult People Diagnosed With Vitiligo
111; 363

Summary

This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.

Eligibility Criteria

Inclusion Criteria

  • All eligible adult patients (aged ≥ 18) registered with General Practioner (GP) practices contributing data to OPCRD between January 1, 2010 and December 31, 2020, were eligible for inclusion in the study. People diagnosed with vitiligo prior to the study period (prevalent vitiligo) and people newly diagnosed with vitiligo during the study period (incident vitiligo) are included as cases.

Exclusion Criteria

  • People actively registered with the GP practice at that date without a history of vitiligo require a minimum one-year registration with their GP practice.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04969419). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search